Colchicine for Heart Health in Coronary Artery Disease

Inclusion Criteria 1. The subject (or legal guardian) understands the trial requirements and treatment procedure, and signs the written informed consent before undergoing any protocol-specified examinations or procedures; 2. Aged ≥18 years; 3. Clinically diagnosed with chronic coronary syndrome (CCS); 4. CCTA confirms ≥50% stenosis in at least one epicardial coronary artery, and CT fractional flow reserve (CT-FFR) \>0.80. Exclusion Criteria 1. Unable or unwilling to provide informed consent; 2. Unable to complete scheduled follow-up; 3. Underwent PCI within the past 3 months; 4. History of coronary artery bypass grafting (CABG); 5. Diagnosis of acute coronary syndromes (ACS); 6. No coronary plaque or plaque stenosis \<50% (confirmed by CCTA); 7. Lesion-specific CT-FFR ≤0.80 in at least one major epicardial coronary artery; 8. Inflammatory bowel disease (Crohn's disease/ulcerative colitis) or chronic diarrhea; 9. History of gastric ulcer or gastric bleeding; 10. Pregnant/lactating women or women of childbearing age without effective contraception; 11. Neuromuscular disease or non-transient creatine kinase (CK) \>3×upper limit of normal (ULN) (confirmed by ≥2 lab tests); 12. Clinically significant non-transient hematological abnormalities (hemoglobin \<100 g/L, hematocrit \<30%/ \>52%, white blood cell count \<3×10⁹/L, platelet count \<100×10⁹/L; confirmed by ≥2 lab tests); 13. Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m² (CKD-EPI formula); 14. Liver dysfunction (alanine aminotransferase \>3×ULN and/or total bilirubin \>2×ULN); 15. Current/planned immunosuppressive therapy; 16. Long-term colchicine use for other indications; 17. Definite/suspected colchicine allergy; 18. Active malignant tumor (expected survival \<1 year); 19. Use of potent CYP3A4/P-glycoprotein inhibitors (e.g., cyclosporine, antiretrovirals, antifungals, erythromycin, clarithromycin) without alternative drugs.